A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass.
bariatric surgery
incretin
microbiota
severe obesity
type 2 diabetes remission
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
03
2023
accepted:
22
09
2023
medline:
3
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
epublish
Résumé
To determine changes in incretins, systemic inflammation, intestinal permeability and microbiome modifications 12 months after metabolic RYGB (mRYGB) in patients with type 2 diabetes (T2D) and their relationship with metabolic improvement. Prospective single-center non-randomized controlled study, including patients with class II-III obesity and T2D undergoing mRYGB. At baseline and one year after surgery we performed body composition measurements, biochemical analysis, a meal tolerance test (MTT) and lipid test (LT) with determination of the area under the curve (AUC) for insulin, C-peptide, GLP-1, GLP-2, and fasting determinations of succinate, zonulin, IL-6 and study of gut microbiota. Thirteen patients aged 52.6 ± 6.5 years, BMI 39.3 ± 1.4 kg/m Patients with obesity and T2D submitted to mRYGB show an enhanced incretin response, a reduced gut permeability and a metabolic improvement, associated with a specific microbiota signature.
Identifiants
pubmed: 37916149
doi: 10.3389/fendo.2023.1181744
pmc: PMC10616869
doi:
Substances chimiques
Glucagon-Like Peptide 1
89750-14-1
C-Peptide
0
Incretins
0
Glucagon-Like Peptide 2
0
Types de publication
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1181744Informations de copyright
Copyright © 2023 Hernández-Montoliu, Rodríguez-Peña, Puig, Astiarraga, Guerrero-Pérez, Virgili, López-Urdiales, Osorio, Monseny, Lazzara, Sobrino, Pérez-Maraver, Pérez-Prieto, Pellitero, Fernández-Veledo, Vendrell and Vilarrasa.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMB Rep. 2016 Oct;49(10):536-541
pubmed: 27530685
Gut Microbes. 2021 Jan-Dec;13(1):1930872
pubmed: 34159880
Diabetes Care. 2009 Nov;32(11):2133-5
pubmed: 19875608
Diabetes. 2013 Dec;62(12):4184-91
pubmed: 23884887
Am J Clin Nutr. 2013 Jul;98(1):16-24
pubmed: 23719559
Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2365-70
pubmed: 19164560
Can J Diabetes. 2020 Jun;44(4):359-367
pubmed: 32057671
Obes Surg. 2019 Mar;29(3):964-974
pubmed: 30402804
Obes Surg. 2017 Feb;27(2):295-302
pubmed: 27440168
Molecules. 2021 Jan 28;26(3):
pubmed: 33525625
Obes Surg. 2017 Apr;27(4):917-925
pubmed: 27738970
Nat Commun. 2016 Apr 13;7:11257
pubmed: 27071849
Surg Obes Relat Dis. 2019 Aug;15(8):1367-1373
pubmed: 31296445
Obes Surg. 2022 Jan;32(1):170-185
pubmed: 34642872
Gut. 2015 Nov;64(11):1744-54
pubmed: 25500202
Surg Obes Relat Dis. 2020 Feb;16(2):175-247
pubmed: 31917200
Biomed Pharmacother. 2020 May;125:109914
pubmed: 32035395
EBioMedicine. 2019 Feb;40:67-76
pubmed: 30639417
Exp Mol Med. 2018 Feb 23;50(2):e450
pubmed: 29472701
Sci Rep. 2019 Mar 20;9(1):4736
pubmed: 30894560
PLoS Comput Biol. 2008 Nov;4(11):e1000217
pubmed: 18989396
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Microbiome. 2017 Mar 3;5(1):27
pubmed: 28253908
J Gastrointest Surg. 2020 Aug;24(8):1736-1746
pubmed: 31388884
Nutrients. 2020 Jan 21;12(2):
pubmed: 31973130
Microbiome. 2020 Feb 7;8(1):13
pubmed: 32033593
Gut. 2011 Sep;60(9):1214-23
pubmed: 21572120
Surg Obes Relat Dis. 2011 Nov-Dec;7(6):691-6
pubmed: 20688578
Diabetol Metab Syndr. 2020 Nov 11;12(1):98
pubmed: 33292434
Endocr Rev. 2019 Oct 1;40(5):1271-1284
pubmed: 31081896
Pharmacogenomics J. 2013 Dec;13(6):514-22
pubmed: 23032991
Nutrients. 2020 May 19;12(5):
pubmed: 32438689
Diabetes Obes Metab. 2022 Jul;24(7):1224-1234
pubmed: 35257467
Diabetes Care. 2013 Jan;36(1):20-6
pubmed: 23033249
J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3619-e3633
pubmed: 33950216
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7911-6
pubmed: 8755576
Surg Obes Relat Dis. 2021 Jan;17(1):231-238
pubmed: 33036939
Nat Methods. 2013 Dec;10(12):1200-2
pubmed: 24076764
Gut. 2009 Aug;58(8):1091-103
pubmed: 19240062
Diabetes. 2013 Sep;62(9):3044-52
pubmed: 23649520
Sci Transl Med. 2013 Mar 27;5(178):178ra41
pubmed: 23536013
Physiol Rev. 2011 Jan;91(1):151-75
pubmed: 21248165
Obes Surg. 2020 Sep;30(9):3536-3548
pubmed: 32447634
Sci Rep. 2021 Dec 10;11(1):23813
pubmed: 34893681
PLoS One. 2012;7(4):e35240
pubmed: 22506074
Clin Transl Med. 2021 Nov;11(11):e575
pubmed: 34841718
Nat Microbiol. 2021 May;6(5):563-573
pubmed: 33820962
Surg Obes Relat Dis. 2019 Nov;15(11):1888-1895
pubmed: 31648978
EBioMedicine. 2016 May;7:112-20
pubmed: 27322465
Am J Clin Nutr. 1991 Nov;54(5):846-54
pubmed: 1951155
Endocrinol Nutr. 2016 Dec;63(10):560-568
pubmed: 27633134
Diabetes Care. 2016 Jun;39(6):893-901
pubmed: 27222547
Obes Surg. 2020 Jun;30(6):2345-2361
pubmed: 32152837
Obes Surg. 2010 Sep;20(9):1245-50
pubmed: 20524158
Can J Diabetes. 2017 Aug;41(4):439-447
pubmed: 28552651
Anaerobe. 2006 Feb;12(1):23-43
pubmed: 16701609
Exp Ther Med. 2019 Mar;17(3):2268-2278
pubmed: 30867711
Genome Med. 2016 Jun 15;8(1):67
pubmed: 27306058
Obes Rev. 2020 Aug;21(8):e13025
pubmed: 32249534
Eur J Endocrinol. 2015 Apr;172(4):R167-77
pubmed: 25416725
Int J Syst Evol Microbiol. 2004 Sep;54(Pt 5):1469-1476
pubmed: 15388697
Hepatology. 2021 Jan;73(1):126-143
pubmed: 32794259
Tissue Barriers. 2016 Oct 21;4(4):e1251384
pubmed: 28123927
Surg Obes Relat Dis. 2020 Jul;16(7):852-862
pubmed: 32360114
J Immunol. 2017 Oct 15;199(8):2976-2984
pubmed: 28893958
World J Gastrointest Surg. 2016 Apr 27;8(4):301-7
pubmed: 27152136
ISME J. 2017 Sep;11(9):2047-2058
pubmed: 28548658
Obes Surg. 2020 May;30(5):1799-1807
pubmed: 32124218